Southwest Airlines' stock just logged its biggest daily gain since 1978, fueled by a decisive break from its past. As bag fees, assigned seating, and new revenue streams take hold, the carrier's bold transformation is winning over Wall Street and setting the stage for a projected profit surge.
JPMorgan raises its price target for Celsius Holdings (CELH) to $77, citing upside potential from its deepening PepsiCo partnership and the expanding distribution of its Alani Nu brand ahead of Q4 earnings.
While Apis Capital's flagship fund posted stellar 2025 returns, its latest investor letter spotlights the ongoing divergence of opinion on AI pure-plays like C3.ai, where heavy investment needs clash with market expectations for profitability.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Pzena Investment Management's latest quarterly commentary reveals its Focused Value Strategy lagged behind the broader value index in Q4 2025, with agricultural sciences firm FMC Corporation highlighted as a key underperformer amid a market dominated by AI and mega-cap stocks.
Realty Income, the 'Monthly Dividend Company,' has now made over 650 consecutive monthly payments to shareholders. While its financials show a robust cushion, rising interest rates and a shifting retail landscape pose questions about the sustainability of its legendary income stream.
Barclays reaffirms its Overweight rating on Meta Platforms, raising its price target to $800, citing robust Q4 recovery and surging ad revenue. The upgrade follows CEO Mark Zuckerberg's announcement of a massive $115B-$135B AI infrastructure investment plan for 2026.
First Pacific Advisors' FPA Crescent Fund disclosed it sold its position in tech giant Microsoft in Q4 2025. The value-focused fund explained the move was driven by a search for greater upside in other AI-related investments, despite acknowledging Microsoft's strong fundamentals.
Investment firm Ashva Capital Management outlines its investment case for The Walt Disney Company in its Q4 2025 letter, highlighting the entertainment giant's enduring value proposition amid near-term market volatility.
In a strategic pivot, Tesla's Q4 earnings call revealed plans to halt Model S and X production at its Fremont plant, repurposing the space for a massive push into humanoid robotics with the Optimus project, as Elon Musk outlines a vision for a million-unit annual output.
Despite a robust 57% return over three years, a deep dive into Warby Parker's financials reveals a significant disconnect between its current share price and intrinsic value estimates, raising questions about its growth trajectory justifying the premium.
Investment firm Giverny Capital Asset Management reduced its stake in industrial manufacturer AMETEK in Q4 2025, highlighting a disciplined approach to valuation as markets remain captivated by AI narratives. The firm's portfolio underperformed major indices, pressured by its underweight stance in mega-cap technology.
Following Federal Reserve clearance and robust Q4 results, Old Second Bancorp's board authorizes a significant share repurchase program. The move amplifies discussions on whether the regional bank's stock, despite steady gains, remains undervalued or if risks in its concentrated Illinois market are being overlooked.
As Nvidia prepares to report its fiscal Q4 earnings on February 25th, investors are weighing whether to buy ahead of the event. While the AI chip leader's long-term story remains compelling, a look at its recent post-earnings stock performance reveals a pattern that favors a measured approach over trying to time the market.
Truist Securities raises its price target on Huntington Bancshares (HBAN) following a robust Q4 performance, as the regional bank forecasts record interest income growth and benefits from improving industry tailwinds.
Wells Fargo lowered its price target on UnitedHealth Group (UNH) following its Q4 report and a disappointing Medicare rate proposal from regulators, highlighting pressures on the healthcare giant's key growth engine.
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.
Jim Saulnier & Associates reduced its position in the Vanguard 0-3 Month T-Bill ETF by over $5.8 million in Q4, yet short-term Treasuries remain a key liquidity component, accounting for over 5% of its portfolio.
While the online marketplace sector posted robust Q3 earnings, investor sentiment remains tepid. Shutterstock's strategic embrace of generative AI and solid financials were overshadowed by a broader sell-off, raising questions about valuation in a shifting digital landscape.
Varonis Systems (VRNS) is set to report Q4 earnings after the bell Tuesday, with investors watching closely for signs of resilience after recent revenue misses and a broader sell-off in cybersecurity stocks.
